A test to predict cancer risk in patients with Barrett's esophagus
Official title: Validation and Early Commercialization of the ENVISAGE Assay, a Prognostic Test for Barrett's Esophagus
Funded at Capsulomics, LLC · NIH-10923931 · Data updated 2026-11-12
This study is testing a new test called the ENVISAGE assay that helps doctors better understand the risk of cancer progression in people with Barrett's esophagus, so they can make more informed decisions about their care.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Capsulomics, LLC NIH-funded |
| Lab location | 1 site (Baltimore, UNITED STATES) |
| Project start | September 15, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $832,997 |
| NIH project number | 5R44DK136424-02 |
| Project ID | NIH-10923931 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Barrett's esophagus who are at risk for progression to esophageal adenocarcinoma.
✕Less likely to help
Patients without Barrett's esophagus or those who have already developed esophageal adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on developing and validating the ENVISAGE assay, a prognostic test designed to assess the risk of cancer progression in patients with Barrett's esophagus. The assay utilizes a DNA methylation-based PCR approach that analyzes specific genetic markers along with patient age to provide a more accurate risk assessment compared to traditional methods. By improving the sensitivity and specificity of cancer risk predictions, this test aims to enhance clinical decision-making for patients at risk of developing esophageal adenocarcinoma. The research will also explore pathways for commercializing this innovative diagnostic tool.
Why it matters
Potential benefit: If successful, this research could provide patients with a more accurate assessment of their cancer risk, leading to better-informed treatment decisions.
How similar studies have gone: Previous studies have shown promising results with similar genetic-based prognostic assays, indicating potential for success in this novel approach.
Where this research is happening
-
Capsulomics, LLC
Baltimore, United States Active
Researchers
- Principal investigator: Laun, Sarah — Capsulomics, LLC
- Study coordinator: Laun, Sarah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.